List of Excipients in API abacavir sulfate, dolutegravir sodium, lamivudine
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing abacavir sulfate, dolutegravir sodium, lamivudine
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| ViiV Healthcare Company | TRIUMEQ | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 | CELLULOSE, MICROCRYSTALLINE | 2030-06-08 |
| ViiV Healthcare Company | TRIUMEQ | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 | FERRIC OXIDE RED | 2030-06-08 |
| ViiV Healthcare Company | TRIUMEQ | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 | FERROSOFERRIC OXIDE | 2030-06-08 |
| ViiV Healthcare Company | TRIUMEQ | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 | MAGNESIUM STEARATE | 2030-06-08 |
| ViiV Healthcare Company | TRIUMEQ | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 | MANNITOL | 2030-06-08 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for abacavir sulfate, dolutegravir sodium, lamivudine
Excipient focus: CELLULOSE, MICROCRYSTALLINE
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A CORN
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing SODIUM STARCH GLYCOLATE TYPE A CORN
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing SODIUM STARCH GLYCOLATE TYPE A CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
abacavir sulfate, dolutegravir sodium, lamivudine drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| ViiV Healthcare Company | abacavir sulfate, dolutegravir sodium, lamivudine | 49702-231 |
| >Company | >Ingredient | >NDC |
abacavir sulfate, dolutegravir sodium, lamivudine drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
